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Collapse of endocannabinoid signaling in
the amygdala underlies stress-induced
anxiety. Qin et al. present a mechanism
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loss of LMO4-dependent inhibition of
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production. Suppressing amygdalar
PTP1B rescues stress-induced anxiety.
Neuron
ArticleChronic Stress Induces Anxiety
via an Amygdalar Intracellular Cascade
that Impairs Endocannabinoid Signaling
Zhaohong Qin,1 Xun Zhou,1 Nihar R. Pandey,1 Haley A. Vecchiarelli,2 Chloe A. Stewart,1 Xia Zhang,3,4 Diane C. Lagace,4
Jean Michel Brunel,5 Jean-Claude Be´ı¨que,4 Alexandre F.R. Stewart,6,7,8 Matthew N. Hill,2 and Hsiao-Huei Chen1,4,8,*
1Ottawa Hospital Research Institute, Ottawa, ON K1H8M5, Canada
2Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Departments of Cell Biology and Anatomy &
Psychiatry, University of Calgary, Calgary, AB T2N4N1, Canada
3Royal Ottawa Mental Health Centre, Ottawa, ON K1Z7K4, Canada
4Department of Cellular and Molecular Medicine, Ottawa, ON K1H8M5, Canada
5Centre de Recherche en Cance´rologie de Marseille, Laboratory of Integrative Structural & Chemical Biology (iSCB), Aix-Marseille Universite´,
13385 Marseille Cedex 5, France
6Department of Biochemistry, Microbiology and Immunology, Ottawa, ON K1H8M5, Canada
7University of Ottawa Heart Institute, Ottawa, ON K1Y4W7, Canada
8Department of Medicine, University of Ottawa, Ottawa, ON K1H8M5, Canada
*Correspondence: hchen@uottawa.ca
http://dx.doi.org/10.1016/j.neuron.2015.02.015SUMMARY
Collapse of endocannabinoid (eCB) signaling in the
amygdala contributes to stress-induced anxiety,
but the mechanisms of this effect remain unclear.
eCB production is tied to the function of the gluta-
mate receptor mGluR5, itself dependent on tyrosine
phosphorylation. Herein, we identify a novel pathway
linking eCB regulation of anxiety through phosphory-
lation of mGluR5. Mice lacking LMO4, an endoge-
nous inhibitor of the tyrosine phosphatase PTP1B,
display reduced mGluR5 phosphorylation, eCB
signaling, and profound anxiety that is reversed by
genetic or pharmacological suppression of amyg-
dalar PTP1B. Chronically stressed mice exhibited
elevated plasma corticosterone, decreased LMO4
palmitoylation, elevated PTP1B activity, reduced
amygdalar eCB levels, and anxiety behaviors that
were restored by PTP1B inhibition or by glucocorti-
coid receptor antagonism. Consistently, corticoste-
rone decreased palmitoylation of LMO4 and its
inhibition of PTP1B in neuronal cells. Collectively,
these data reveal a stress-responsive corticoste-
rone-LMO4-PTP1B-mGluR5 cascade that impairs
amygdalar eCB signaling and contributes to the
development of anxiety.
INTRODUCTION
Mood and anxiety disorders represent one of the largest health
burdens on society today, yet few novel therapeutics have
emerged in the past two decades. Neuroimaging has delineated
disturbances in the limbic circuit composed of the amygdala,prefrontal cortex (PFC) and hippocampus underlying the patho-
physiology of these conditions (Etkin et al., 2009). The current
evidence points to hyperexcitability of the amygdala, due in
part to impairments in the inhibitory influence of the hippocam-
pus and PFC, as germane to the manifestation of these diseases
(Etkin et al., 2009; Kim et al., 2011). While most research has
focused on how afferent regulation to the amygdala is disturbed
in anxiety, few studies have examined intrinsic changes within
amygdalar neurons that could account for hyperexcitability of
this structure. As such, characterizing signaling mechanisms in
the amygdala that regulate anxiety behavior is key to identifying
putative substrates dysregulated in pathological conditions.
In this regard, the endocannabinoid (eCB) system has recently
become an interesting player in the regulation of stress and
anxiety. Cannabis consumption in humans can have profound
effects on anxiety, and similarly, preclinical studies have found
that modulation of eCB signaling alters anxiety (Hill and Patel,
2013). Genetic or pharmacological disruption of eCB signaling
produces an array of neurobehavioral effects that mirror those
produced by exposure to stress, such as increased activation
of the hypothalamic-pituitary-adrenal (HPA) axis, elevated levels
of anxiety, altered stress-coping behaviors, and impairments in
fear extinction (Marsicano et al., 2002; Patel et al., 2004; Shon-
esy et al., 2014; Steiner et al., 2008). Most, if not all, of these ef-
fects are replicated by local disruption of eCB signaling directly
within the amygdala (Gunduz-Cinar et al., 2013). Specifically,
administration of a CB1 receptor antagonist directly into the ba-
solateral nucleus of the amygdala (BLA) results in an increase in
HPA axis activity, elevated levels of anxiety and a disruption of
fear extinction (Dono and Currie, 2012; Ganon-Elazar and Akirav,
2009; Hill et al., 2009). This suggests that eCB signaling within
the BLA constrains activation of the stress response and anxiety.
Consistent with this stress-buffering role of eCB signaling,
several reports indicate that facilitation of eCB signaling can
reverse the adverse effects of chronic stress (Bortolato et al.,
2007; Hill et al., 2013; Lomazzo et al., 2015; Sumislawski et al.,Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc. 1319
Figure 1. LMO4KO Mice Have a Stresslike
Anxiety Phenotype with Impaired Fear
Extinction
(A–D) EPM (A), LDP test (B), OF test (C), and
novelty suppressed feeding (D) revealed a marked
anxiety phenotype in LMO4KO (CamK2aCre//
LMO4flox/flox) mice compared with littermate con-
trol ‘‘WT’’ mice (LMO4flox/flox).
(E) Locomotor activity, measured by beam break
over a 2 hr period, was similar between littermate
KO and WT mice.
(F) LMO4KO mice showed impaired fear extinc-
tion in the passive avoidance task but no differ-
ence at the level of pain threshold compared with
WT mice.
Co, conditioning training day. *p < 0.05. Error bars
represent SEM. Number of mice used indicated
in bars.2011; Zhang et al., 2015). More specifically, exposure to stress
results in a sustained collapse of eCB signaling within the amyg-
dala and leads to pathological states of anxiety (Hill et al., 2013).
Conversely, extrinsic modalities such as environmental enrich-
ment, dietary polyunsaturated fatty acids, and pharmacological
agents (such as salvinorin) that reduce anxiety alter eCB meta-
bolism or signaling within the BLA (Braida et al., 2009; El Rawas
et al., 2011; Yamada et al., 2014). Together, these studies indi-
cate that amygdalar eCB signaling is an important regulator of
anxiety.
It is well established that the production of eCB is tied to the
activity of themetabotropic glutamate receptors (mGluR), partic-
ularly mGluR5 (Maccarrone et al., 2008; Maejima et al., 2005;
Zhu and Lovinger, 2005). In the case of mGluR5, its phosphory-
lation at tyrosine residues is required for maximal signaling
(Orlando et al., 2002; Tozzi et al., 2001), suggesting that a reduc-
tion in phosphorylation could result in consequential effects on
eCB production and signaling. Recently, we demonstrated that
the LIM domain only 4 (LMO4) protein is an endogenous inhibitor
of the protein tyrosine phosphatase PTP1B in the hypothalamus
(Pandey et al., 2013; Pandey et al., 2014); however, the impact of
PTP1B activity on mGluR5 phosphorylation, and its downstream
effects on eCB signaling, have yet to be determined. Of note,
90% of neurons within the BLA are glutamatergic (Carlsen,
1988) and express high levels of LMO4 (Maiya et al., 2012).
Interestingly, a partial deletion of LMO4 within the BLA has
recently been linked to the regulation of fear learning (Maiya1320 Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc.et al., 2012). Together, these data bring
forth the previously untested hypothesis
that intracellular signaling cascades that
regulate mGluR5 signaling could affect
anxiety and fear behavior through regula-
tion of eCB signaling.
Using a multidisciplinary approach,
catalyzed by the discovery of a profound
anxiety phenotype in mice deficient
in LMO4 within glutamatergic neurons,
our studies elucidate an intracellular
signaling cascade whereby chronicstress, through a glucocorticoid-mediated pathway, impairs
LMO4-mediated inhibition of PTP1B activity, leading to collapse
of eCB production (through a loss of mGluR5 phosphorylation)
within the amygdala and causing anxiety behavior. Accordingly,
this cascademay represent an entirely novel target for the devel-
opment of anxiolytic pharmacotherapeutic agents.
RESULTS
LMO4 Knockout Mice Have Increased Anxiety and
Impaired Fear Extinction
Deletion of LMO4 within glutamatergic neurons (CamK2aCre//
LMO4flox/flox; LMO4 knockout [LMO4KO]; Figures S1A and
S1B) resulted in an anxiety phenotype in four behavioral tests,
including (1) a reduced number of entrances and time spent in
the open arms during the elevated plus maze (EPM) test (Fig-
ure 1A), (2) a reduced number of transitions between the dark
and light chambers in the light/dark preference (LDP) test (Fig-
ure 1B), (3) less time spent in the center during the open-field
(OF) test (Figure 1C), and (4) increased latency to feed in an
OF, but not in the home cage, in the novelty suppressed feeding
test (Figure 1D). The anxious phenotype in LMO4KO mice is not
due to altered basal locomotor activity (Figure 1E). Impaired fear
extinction was also present in LMO4KOmice, tested by the pas-
sive avoidance task (Figure 1F), and this was not due to a differ-
ence in pain threshold. Collectively, these data suggest that
LMO4KO mice have an emotional phenotype that parallels the
Figure 2. Impaired eCB Signaling Is Associ-
ated with Anxiety Phenotype in LMO4KO
Mice
(A–C) Anxiety and fear extinction phenotype in
LMO4KO mice look strikingly similar to WT mice
treated with the CB1cannabinoid receptor antag-
onist AM251 (3 mg/kg), and the anxiogenic effect
of AM251 in WT mice was occluded in LMO4KO
mice. Mice were subjected to EPM test 20 min
after intra-peritoneal (ip) injection of either vehicle
or AM251, followed by OF test 48 hr later. The fear
extinction test was carried out in a separate group
of mice. Vehicle or AM251 was injected (ip) 20 min
before the first extinction trial. Exponential curve
fits of latencies are presented above the bars.
Co, conditioning training day. Ext2-15, extinction
testing days 2 to 15.
(D) DSI was reduced in BLA neurons of LMO4KO
mice. The reduction was also observed in WT neu-
rons but occluded in LMO4KOneurons treatedwith
the CB1 cannabinoid receptor antagonist AM251.
(Top left) Positions of recording and stimulating
electrodes for patch-clamp recording. BLA, baso-
lateral amygdala; CeA, central amygdala; LA, lateral
amygdala; RE, recording electrode; SE, stimulating
electrode. (Top right) Sample traces of IPSCs.
(E) Treatment of BLA neurons with CB1 agonist
HU210 (500 nM) reduced eIPSC amplitude to a
similar degree.
(F) WT and LMO4KO BLA neurons have similar
dose-dependent responses to HU210.
(G and H) Ip treatment with the CB1 agonist HU210
(10 mg/kg) abolished the anxiety phenotype (G) or
fear extinction deficit (H) of LMO4KOmice. Vehicle
or drugwas delivered (ip) 20min before EPM test or
each extinction trial.
*&#p < 0.05. Error bars represent SEM.behavioral changes that emerge following stress exposure, such
as increased anxiety and impaired fear extinction.
The Anxiety and Fear Extinction Phenotypes in LMO4KO
Mice Are due to Reduced mGluR-Mediated eCB
Signaling
Interestingly, the anxiety and fear extinction phenotypes in
LMO4KO mice look strikingly similar to those observed in CB1
receptor knockout (KO) mice (Haller et al., 2004; Marsicano
et al., 2002), so we sought to determine whether eCB function
was altered in LMO4KO mice. The CB1cannabinoid receptor
antagonist AM251 had a profound anxiogenic effect in wild-
type (WT) mice, but this effect was occluded in LMO4KO mice
in both the EPM and OF tests (Figures 2A–2C). As eCB signaling
in the BLA has been linked to both anxiety and fear extinction (Hill
et al., 2013; Marsicano et al., 2002), we examined if changes in
eCB signaling were present in the amygdalae of LMO4KONeuron 85, 1319–1331mice. Whole-cell recordings of BLA
neurons ex vivo in brain slices showed
that depolarization-induced suppression
of inhibition (DSI), an electrophysiological
signature of eCB signaling that is blocked
by the CB1 receptor antagonist AM251,was reduced in LMO4KO mice (Figure 2D). Similarly, another
measure of eCB signaling, depolarization-induced suppression
of excitation (DSE) was also impaired in LMO4KO mice (Fig-
ure S2). These results indicate that amygdalar eCB function is
impaired in LMO4KO mice.
To address whether the impairments in eCB signaling were
mediated by altered CB1 receptor signaling capacity versus
eCB biosynthesis/mobilization, we examined each of these vari-
ables separately. To assess the functionality of CB1 receptors,
we administered an exogenous CB1 receptor agonist, HU210,
to BLA slices. LMO4KO and WT BLA neurons showed a similar
reductionof amplitudeof inhibitory postsynaptic currents (IPSCs)
(Figure 2E) and a similar dose response to HU210 (Figure 2F),
indicating that CB1 receptor function is not impaired in LMO4KO
BLA neurons. Consistent with this finding, administration of
HU210 rescued the anxiety phenotype (Figure 2G) and restored
fear extinction (Figures 2H and S3) in LMO4KO mice., March 18, 2015 ª2015 Elsevier Inc. 1321
Figure 3. mGluR-Dependent eCB Mobiliza-
tion Is Impaired in LMO4KO Amygdala
(A) 2-AG but not AEA levels in amygdala in
LMO4KO mice were reduced. n = 5 per group.
(B) DHPG increased the PPR (P2/P1) inWT but not
in LMO4KO BLA neurons, and this effect was
blocked by pre-treatment with CB1R antagonist
AM251. Current traces depicting GABA-mediated
eIPSCs induced by paired pulses before and
15 min after DHPG application from WT and
LMO4KO BLA neurons with or without AM251 are
shown above the graph; the scale bar represents
200 pA/50 ms.
(C) DHPG-induced long-term depression of IPSC
(LTDi) was markedly attenuated in LMO4KO
compared with littermate control (WT) BLA neu-
rons. LTDi was blocked by the AM251 in WT BLA
neurons. Representative traces before (trace 1:
black for WT and red for KO) and 15 min after
DHPG treatment (trace 2: light gray for WT and
light pink for KO) or recovery after DHPG-wash
(trace 3: dark gray forWT and dark pink for KO) are
shown above the graph; the scale bar represents
100 pA/10 ms.
(D) Change of holding current following admin-
istration of the mGluR1/5 agonist DHPG was
markedly attenuated in LMO4KO compared with
control BLA neurons. The mGluR5 antagonist
MPEP blocked the DHPG-induced change of
holding current. Number of cells recorded in
parentheses or indicated in bars.
*p < 0.05. Error bars represent SEM.Given that the function of CB1 receptors appears intact in
LMO4KO mice, the deficit in eCB function may arise from
reduced eCB levels. To that end, we carried out liquid chroma-
tography-mass spectrometry analysis of amygdala samples
and found that tissue levels of 2-arachidonoylglycerol (2-AG),
but not anandamide (AEA), were reduced in LMO4KO mice
(Figure 3A). Because 2-AG production is tied to the activity
of mGluR5 (Maccarrone et al., 2008), we then examined if
mGluR5-mediated eCB signaling was altered in LMO4KO
mice. Consistent with previous reports (Maccarrone et al.,
2008; Maejima et al., 2005; Zhu and Lovinger, 2005), DHPG
increased the paired pulse ratio (PPR) and induced inhibitory
long-term depression (LTDi) in WT mice. Both responses reflect
mGluR5-dependent eCB-mediated alteration in synaptic GABA
release (Azad et al., 2004; Marsicano et al., 2002) and were
blocked by pretreatment with the CB1R antagonist AM251
(Figures 3B and 3C). These effects of DHPG on the PPR and
LTDi were markedly reduced in BLA neurons of LMO4KO mice
(Figures 3B and 3C), indicating that mGluR5-mediated eCB
signaling within the BLA is impaired following ablation of LMO4.
Activation of mGluR5 with DHPG is known to induce inward
currents, likely mediated by opening of non-selective cationic
channels (Fagni et al., 2000; Gee et al., 2003; Gue´rineau et al.,
1994). Consistent with our findings of impairedmGluR5 signaling
in LMO4KO mice, the DHPG-induced inward current was
markedly reduced in LMO4KO BLA neurons compared with
WT (Figure 3D). Together, these findings lead us to conclude
that impaired eCB signaling in BLA neurons of LMO4KO mice
could be due to impairments in mGluR5 signaling.1322 Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc.LMO4 Inhibition of PTP1B Activity Regulates
mGluR5-Mediated eCB Signaling
Given that lower 2-AG levels were associated with reduced
mGluR5 mediated eCB signaling in LMO4KO BLA neurons, we
examined how mGluR5 function is regulated by LMO4. It has
been reported that activation of mGluR5 signaling involves
phosphorylation of its tyrosine residues (Orlando et al., 2002;
Tozzi et al., 2001). Interestingly, we recently demonstrated that
LMO4 is required to suppress the activity of the protein tyrosine
phosphatase PTP1B in the hypothalamus (Pandey et al., 2013).
Thus, we postulated that elevated PTP1B activity resulting
from LMO4 ablation would lead to impaired mGluR5 function
through a dephosphorylation of tyrosine residues, thus reducing
mGluR5 signaling. Consistent with our previous study, an in vitro
assay revealed a 3-fold elevation of PTP1B tyrosine phospha-
tase activity in amygdala lysates from LMO4KOmice (Figure 4A).
This change in PTP1B activity was not due to elevated PTP1B
protein levels (Figure 4B). Instead, it reflected lower levels of
the oxidized, inactive form of PTP1B in LMO4KO amygdala
compared with littermate controls (Figure 4B), consistent with
our notion that LMO4 promotes the inactivation of PTP1B
through oxidation of a cysteine residue in the catalytic domain
(Pandey et al., 2013).
We confirmed that mGluR5 is phosphorylated at tyrosine res-
idues (Figure 4C). Furthermore, we showed that PTP1B targets
and dephosphorylates mGluR5 and that LMO4 modulates this
process (Figure 4C). Endogenous mGluR5 was immunoprecipi-
tated from F11 neuronal cells and shown to be phosphorylated
at tyrosine residues using a phosphotyrosine-specific antibody
Figure 4. Knockdown of LMO4 Causes Elevated PTP1B Activity, Reduced Phosphorylation of mGluR5 at Tyrosine Residues, and Impaired
mGluR5-Dependent eCB Signaling
(A) PTP1B activity is elevated in LMO4KO amygdala. n = 8 per group. *p < 0.05. Error bars represent SEM.
(B) PTP1B protein levels are not changed. Rather, there was less oxidized PTP1B (oxi-pTP1B) in the amygdala of LMO4KO compared with littermate controls. n =
3 per genotype.
(C) F11 neuronal cells transfected with PTP1B expression vector (lane 3) or LMO4shRNA (lane 8) caused reduced tyrosine phosphorylation of mGluR5.
(D) Transient transfection of F11 neuronal cells with LMO4shRNA reduced (lanes 4–6), whereas LMO4 overexpression (lanes 10–12) increased DHPG-induced
ERK phosphorylation. For (C) and (D), n = 3 experiments. *p < 0.05 compared with lane 1 after Bonferroni correction for multiple testing. #p < 0.05.
(E) Endogenous mGluR5 in F11 neuronal cells was pulled down (PD) with a substrate-trapping mutant (D/A) of GST-tagged PTP1B protein.
(F) Flag-tagged LMO4 is co-immunoprecipitated (IP) withmGluR5 in F11 cells. The pre-immunoprecipitation cell extracts (Pre) were probedwithmGluR5 and Flag
antibodies. In (B), (C), and (F), blots are quantified on the right.
(G) mGluR5 tyrosine phosphorylation is reduced in LMO4KO amygdala. Amygdala extracts pooled from three littermateWT and three pooled LMO4KO (KO) mice
were IPwithmGluR5 antibody and immunoblots (IB) were probedwith antibodies to p-Tyr ormGluR5. An unrelated antibody (anti-IRF2BP2; Teng et al., 2010) was
used as an IP control. Input represents 1/10 of amygdala extracts directly loaded without IP.
Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc. 1323
Figure 5. The PTP1B Inhibitor Trodusquemine Normalizes PTP1B Activity, Restores mGluR Function, and Alleviates the Anxiety Phenotype
of LMO4KO Mice
(A) Pre-treatment with trodusquemine (10 mM) for 30 min restored ERK phosphorylation in response to mGluR1/5 agonist DHPG in F11 neuronal cells. Blots are
quantified on the right. n = 3 experiments. *p < 0.05 compared with lane 1 after Bonferroni correction for multiple testing. #p < 0.05.
(B) Trodusquemine restored the facilitation of PPR in response to 10 min of bath applied DHPG in LMO4KO BLA neurons.
(C and D) Addition of trodusquemine (10 uM) in the intracellular recording electrode rescued DHPG-induced holding currents (C) and restored DSI (D) in LMO4KO
BLA neurons.
(legend continued on next page)
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(lane 1). mGluR5 tyrosine phosphorylation was markedly
reduced by PTP1B overexpression (lane 3), and this effect was
blocked by pervanadate, a tyrosine phosphatase inhibitor
(lane 4). Importantly, overexpression of LMO4 increased
(lane 5) whereas knockdown of LMO4 reduced mGluR5 tyrosine
phosphorylation (compare lanes 8 and 7). Thus, modulation of
LMO4 affects mGluR5 phosphorylation. As a functional assay
of mGluR5 activity, we also found that DHPG-induced ERK
phosphorylation (Kim et al., 2008) was blunted following LMO4
knockdown by small hairpin RNA (shRNA) (Figure 4D, compare
lanes 5 and 6 with lanes 2 and 3) and augmented by overexpres-
sion of LMO4 in neuronal cell lines (Figure 4D, compare lanes 10–
12 with lanes 7–9). Pull-down assays demonstrated that both
LMO4 and PTP1B associate with mGluR5 (Figures 4E and 4F).
Using a catalytically inactivated mutant of PTP1B that binds,
but does not dephosphorylate or release its substrate (i.e., a sub-
strate-trapping mutant), we observed a strong interaction of this
mutant PTP1B with mGluR5 in a glutathione S-transferase (GST)
pull-down assay (Figure 4E). This demonstrates that mGluR5 is a
bona fide substrate of PTP1B and argues that PTP1B is an
endogenous regulator of mGluR5 signaling. We also demon-
strated through co-immunoprecipitation that mGluR5 interacts
with LMO4 (Figure 4F), suggesting that LMO4 may regulate
mGluR5 function in a complex with PTP1B. Consistent with the
elevated PTP1B activity (Figure 4A), we also observed reduced
tyrosine phosphorylation ofmGluR5 in the amygdala of LMO4KO
mice (Figure 4G). Collectively, these results suggest that LMO4
affects mGluR5 signaling through PTP1B activity.
The PTP1B Inhibitor Trodusquemine Normalizes PTP1B
Activity, Restores mGluR5 Function, and Alleviates the
Anxiety Phenotype of LMO4KO Mice
Because ablation of LMO4 is associated with elevated PTP1B
activity and reduced mGluR5 phosphorylation and function,
we next determined the effect of pharmacological ablation of
PTP1B activity on the effects of LMO4 deletion. Using a small-
molecule PTP1B-specific inhibitor, trodusquemine, we demon-
strated that inhibition of PTP1B restored tyrosine phosphoryla-
tion of mGluR5 in LMO4 knockdown cells (Figure 5A, compare
lanes 7 and 8 with lanes 5 and 6). Moreover, trodusquemine
restored DHPG-induced ERK phosphorylation (compare lanes
8 and 6). These results further demonstrated that PTP1B activity
affects mGluR5 phosphorylation and associated signaling.
Consistent with this, trodusquemine restored DHPG-induced
facilitation of the PPR (Figure 5B), neuronal depolarization (Fig-
ure 5C), and DSI (Figure 5D) in LMO4KOBLA neurons and amyg-(E) 2-AG levels in amygdala of LMO4KO mice increased 1hr after ip injection of t
(F and G) A single bilateral stereotaxic injection of trodusquemine to the amygda
after intra-amygdalar injection and (G) extinguished anxiety phenotypes of LMO4K
(OF) after treatment.
(H) The anxiolytic effect of trodusquemine was abolished by the CB1 antagonist A
trodusquemine with vehicle or AM251. Error bars represent SEM.
(I) Seven days after ip injection of trodusquemine (Qin et al., 2015), LMO4KOmice h
novelty suppressed feeding test. Error bars represent SEM.
(J) Trodusquemine’s effect to rescue fear extinction in LMO4KO mice lasts up to
trial. Exponential curve fits of latencies are presented above the bars.
*p < 0.05. Error bars represent SEM. Number of mice used indicated in bars.dalar 2-AG content in LMO4KOmice (Figure 5E). Continuing with
this line of reasoning, we next investigated whether local PTP1B
inhibition within the amygdala might relieve the anxiety pheno-
type of LMO4KO mice. Trodusquemine was delivered by bilat-
eral stereotactic injection to the amygdala and this effectively
blocked excess PTP1B activity in LMO4KO amygdala (Fig-
ure 5F). Similarly, intra-amygdalar trodusquemine completely
abolished the anxiety phenotype of LMO4KOmice, as assessed
in the EPM, LDP, and OF tests (Figure 5G). Of note, this dose of
trodusquemine had no effect on PTP1B activity or behavior in
littermate controls (Figure 5G). Importantly, the anxiolytic effect
of trodusquemine was blocked by the CB1 antagonist AM251
(Figure 5H), demonstrating that the anxiolytic effect of trodus-
quemine works through a restoration of eCB signaling within
the amygdala. Because trodusquemine can pass the blood-
brain barrier (Ahima et al., 2002; Lantz et al., 2010), the anxiolytic
effect of trodusquemine was also reproducibly observed in
LMO4KO mice following systemic intra-peritoneal injection, as
shown by three anxiety tests (Figure S5), as well as by novelty
suppressed feeding test (Figure 5I) and by the passive avoidance
test (Figures 5J and S6). Consistent with our model, the anxio-
lytic effect of trodusquemine was also blocked by a low dose
of the mGluR5 antagonist MPEP (Figure S7). Of note, this low
dose of MPEP on its own did not affect behavior (Figure S7).
Taken together, these results indicate that by inhibiting the
phosphatase activity of PTP1B, trodusquemine restores tyrosine
phosphorylation of mGluR5 and its activity, which in turn ele-
vates 2-AG signaling within the amygdala and alleviates the
anxiety phenotype of LMO4KO mice.
shRNA Knockdown of PTP1B in the Amygdala Relieves
the Anxiety Phenotype of LMO4KO Mice
To further demonstrate that PTP1B in the BLA participates in this
process, we examined the effects of genetic PTP1B knockdown
in LMO4KO mice. Twenty-one days after a bilateral stereotactic
injection of lentiviral vectors expressing PTP1B shRNA and GFP
into the amygdala (Figure 6A), there was markedly reduced
PTP1B protein expression (Figure 6B) and PTP1B activity (Fig-
ure 6C) in amygdala extracts. PTP1B shRNA extinguished the
anxiety phenotypes of LMO4KO mice in the EPM (Figure 6D),
the LDP (Figure 6E), and the OF (Figure 6F) tests. In contrast,
the control lentiviral vector-injected LMO4KO mice displayed an
anxiety phenotype in all tests (Figures 6D–6F). Through conver-
gent pharmacological and genetic approaches, these studies
confirm the importance of PTP1B activity within the amygdala in
mediating the emotional changes evoked by ablation of LMO4.rodusquemine.
la (see Figure S5) (F) normalized PTP1B activity in LMO4KO amygdala 1 week
Omice. Behavior tests were conducted 1 day (EPM), 3 days (LDP), and 5 days
M251. The EPM test was conducted 24 hr after intra-amygdalar coinjection of
ave normalized latency spent in theOF arena before first feeding episode in the
7 days. Saline or trodusquemine was injected (ip) 1hr before the first extinction
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Figure 6. Intra-Amygdalar Injection of Lentiviral PTP1B shRNA Alleviates the Anxiety Phenotype of LMO4KO Mice
(A) Representative live images of GFP-positive BLA neurons 21 days after intra-amygdalar injection of lentiviral vectors expressing GFP reporter and PTP1B
shRNA. (Top) Bright field; (bottom) merged differential interference contrast and fluorescence. The scale bars represent 1 mm.
(B) Western blot of amygdalar extract revealed a reduction in PTP1B protein expression 21 days after intra-amygdalar injection of lentiviral vector expressing
PTP1B shRNA compared with control shRNA (CtlshRNA). Blots are quantified in the lower panel. n = 3 experiments. *p < 0.05 relative to ctlshRNA.
(C) PTP1B activity assay 21 days after lentiviral vector injection.
(D–F) Bilateral stereotaxic injection of PTP1B shRNA (1 3 109 TU/ml, 0.4 ml/side) to the amygdala extinguished anxiety phenotypes of LMO4KO mice (red bars)
and had no effect in WT mice (black bars). Behavior tests were conducted 12 days (D, EPM), 14 days (E, LDP), and 16 days (F, OF) after treatment.
*p < 0.05. Error bars represent SEM.Stress-Induced Corticosterone Disrupts the
LMO4-PTP1B Cascade to Impair eCB Signaling
and Increase Anxiety
The above experiments demonstrate that the loss of LMO4 in-
creases PTP1B activity, which dephosphorylates mGluR5 and
consequently reduces eCB signaling within the amygdala. This
impairment in mGluR5 and eCB signaling, in turn, results in an in-
crease in anxiety and impairments in fear extinction. This pheno-
type of the LMO4KO mouse is reminiscent of the effects seen
following chronic stress or a loss of eCB signaling (Hill et al.,
2013; Marsicano et al., 2002; McEwen, 2005). We, and others,
have previously found that the ability of chronic stress to modu-
late emotional behavior is mediated through a breakdown in
eCB signaling (Bortolato et al., 2007; Hill et al., 2013; Lomazzo
et al., 2015; Sumislawski et al., 2011; Zhong et al., 2014). Having
identified LMO4 and PTP1B as regulators of eCB signaling, we
further sought to determine if LMO4 and/or PTP1B levels were
altered by stress. To that end, WTmice were subjected to a daily
30 min regimen of restraint stress for 8 days that caused a signif-
icant increase in the levels of the blood stress hormone cortico-
sterone (CORT; Figure 7A). Interestingly, this chronic stress
regimenwasalso found toelevatePTP1Bactivity in theamygdala
(Figure 7B), not by altering PTP1B expression but rather by pre-
venting the formation of the oxidized inactive form of PTP1B,
that is, increasing the levels of active PTP1B enzyme (Figure 7C).1326 Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc.Previously, we demonstrated that LMO4 inhibits PTP1B activity
by maintaining the oxidized inactive form of PTP1B. This inhibi-
tion depends on LMO4 retention at the endoplasmic reticulum
through palmitoylation of its C-terminal cysteine residue (Pandey
et al., 2013). Consistent with activation of PTP1B, LMO4 palmi-
toylation was markedly reduced after chronic stress (Figure 7C).
To address whether glucocorticoids are involved in elevating
PTP1B activity from stress exposure, cultured neuronal cells
were exposed to CORT for 6 hr. This acute treatment increased
PTP1B activity (Figure 7D) by reducing oxi-PTP1B levels and
LMO4 palmitoylation (Figure 7E). Reduced palmitoylation
caused LMO4 to translocate from the cytosol to the nucleus,
preventing LMO4 from interacting with PTP1B at the cytoplasm
(Figure 7F). Collectively, these data demonstrate that glucocorti-
coids reduce palmitoylation of LMO4, impairing its ability to
interact with and maintain oxidized PTP1B, which in turn results
in an increase in PTP1B activity.
To determine if this increase in PTP1B activity contributed to
stress-induced changes in eCB signaling and anxiety behavior,
we examined the effects of PTP1B inhibition on eCB levels
and found that it attenuated the stress induced reductions in
the amygdalar tissue content of both AEA and 2-AG levels (Fig-
ure 7G). Consistent with this reversal of impaired eCB
signaling, we also found that inhibition of PTP1B reversed
stress-induced anxiety as measured by the novelty suppressed
Figure 7. PTP1B Activity Is Elevated in Repeatedly Stressed WT Mice and Trodusquemine Alleviates Stress-Induced Anxiety Phenotype
(A) Elevated corticosteroid (CORT) in repeatedly (8 days) immobilization stressed (s) WT male mice compared to unstressed (u) mice.
(B) Elevated PTP1B activity in amygdala of repeatedly (8 days) immobilization stressed WTmale mice, compared with unstressed mice. For (A) and (B), n = 5 to 8
per group.
(C) Immunoblots show lower levels of oxi-PTP and palmitoylated LMO4 (Palm-LMO4) in amygdalae of stressed mice. n = 3 per genotype. *p < 0.05.
(D) PTP1B activity is elevated in F11 neuronal cells after 6 hr treatment with CORT (1 mM = 346 ng/ml). n = 6 per group.
(E) Immunoblots show lower levels of oxi-PTP and Palm-LMO4 in CORT-treated F11 cells. n = 3 experiments per condition. Blots are quantified on the right in (D)
and (E).
(F) CORT treatment causes LMO4 to translocate from the cytoplasm to the nucleus, thereby preventing its interaction with yellow fluorescent protein-tagged
PTP1B at the cytoplasm. The scale bar represents 15 mm.
(G) 2-AG levels are restored in amygdala 1hr after trodusquemine treatment via ip injection.
(H) Repeated restraint stress (8 days) increased latency to feeding in the open arena of the novelty suppressed feeding test. Trodusquemine normalized the
latency. Latency in the home cage was not different. *p < 0.05. Error bars represent SEM.
(I and J) RU486 (30mg/kg) administered by intraperitoneal injection every other day (4 doses) normalized amygdalar PTP1B activity (I) and ameliorated stress-
induced anxiety behavior (J).
(K) A working model of CORT-LMO4-PTP1B-mGluR5-eCB cascade in stress-induced anxiety disorders. (Left) In non-anxious mice, membrane-anchored
palmitoylated LMO4 inhibits PTP1B activity and maintains mGluR5 phosphorylation and function. Activation of mGluR5 mobilizes eCB production and release.
eCB binds to CB1 receptors at the presynaptic site and inhibits neurotransmitter release. (Right) Chronic stress induces glucocorticoids (CORT) that block LMO4
palmitoylation, prevent LMO4 from interacting with PTP1B and unleash the activity of PTP1B. PTP1B dephosphorylates mGluR5 and impairsmGluR5-dependent
eCB production and signaling. GR, membrane-bound glucocorticoid receptor.feeding test (Figure 7H). To confirm the role of corticosterone in
this process in vivo, we tested whether this cascade is depen-
dent on a glucocorticoid mechanism. Consistent with our
model, treatment with the glucocorticoid receptor antagonist
RU486 during chronic stress normalized PTP1B activity within
the amygdala (Figure 7I) and reversed stress-induced anxietyas measured by the novelty suppressed feeding test (Fig-
ure 7J). Collectively this study has identified a novel glucocor-
ticoid-responsive LMO4-PTP1B signaling pathway within the
amygdala that regulates anxiety through an eCB mechanism.
This pathway is potentially relevant for pathological changes
in anxiety occurring in response to chronic stress (Figure 7K).Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc. 1327
DISCUSSION
Herein, we have demonstrated a novel intracellular signaling
cascade within the amygdala that regulates anxiety behavior
(see Figure 7K for model). Our data indicate that within the BLA,
the intracellular protein LMO4 constrains the activity of PTP1B.
Loss of LMO4 results in an increase in PTP1B activity (through
a reduction inoxidationof this phosphatase),which subsequently
results in dephosphorylation of mGluR5. The dephosphorylation
ofmGluR5 impairsmGluR5signaling,which subsequently results
in a suppression of 2-AG mediated eCB signaling. In turn, the
suppression of eCB signaling within the amygdala results in the
manifestation of a stresslike state characterized by elevated
anxiety and impairments in fear extinction. Because a collapse
of eCB signaling within the amygdala following chronic stress
has already been associated with the development of anxiety
(Hill et al., 2013), we subsequently demonstrated the importance
of the LMO4-PTP1B cascade in this process. Specifically, our
data reveal that a glucocorticoid-dependentmechanism reduces
LMO4 function following chronic stress, resulting in elevated
PTP1B activity that caused a suppression of eCB signaling and
the emergence of anxiety. Importantly, inhibition of PTP1B either
by a small-molecule antagonist or by an shRNA knockdown
within the amygdala was capable of rescuing this behavioral
deficit. Collectively, these data shed new light on intracellular
signaling pathways within the amygdala that regulate anxiety
and propose a potential novel mechanism by which chronic
stress modulates eCB signaling and anxiety.
Several lines of evidence have clearly identified that eCB
signaling within the amygdala regulates stress, anxiety, and
emotional behavior (Gunduz-Cinar et al., 2013). Impairments in
amygdalar eCB signaling can increase anxiety, HPA axis activity
and impair fear extinction (Ganon-Elazar and Akirav, 2009; Hill
et al., 2009; Shonesy et al., 2014), all of which are hallmark indices
of stress. The rather serendipitous discovery that mice lacking
LMO4 within glutamatergic neurons exhibit a behavioral pheno-
type that parallels the effects of stress, as well as the phenotype
of CB1 receptor deficient mice, prompted us to explore whether
eCB signaling was themechanism underlying this effect. Consis-
tent with these parallels, we discovered that the loss of LMO4
fromglutamatergic neurons resulted in a reduction in both the tis-
sue level of the eCBmolecule 2-AG, as well as synaptic plasticity
driven by eCB signaling within the amygdala. The fact that this
deficit appeared to be mediated by alterations in the presumed
synthesis of 2-AG, and not compromised CB1 receptor function,
led us to test whether heightened anxiety could be overcome by
exogenous administration of a CB1 receptor agonist in these
mice. Indeed,we found that CB1 receptor agonism in LMO4-defi-
cient mice completely alleviated the anxiety behavior, indicating
that this phenotype was driven by impairments in eCB biosyn-
thesis and/or mobilization. This is consistent with a recent report
demonstrating that genetic ablation of 2-AG synthesis, which
reduced 2-AG levels in the amygdala among other brain regions,
resulted in an impairment in DSE within the amygdala as well as
resulted in elevated anxiety (Shonesy et al., 2014). Together,
these studies would suggest that tonic 2-AG signaling within
the amygdala may be necessary to maintain synaptic plasticity
and govern anxiety-like behavior; a disruption of this signal could1328 Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc.result in aberrant excitability of this structure and the emergence
of a state of heightened anxiety.
Our findings contrast that of a recent paper (Maiya et al., 2012)
in which a partial knockdown of LMO4 was found to have no
effect on unconditioned anxiety as assessed by many of the
same tests used herein. This difference is likely due to the degree
or cell-type-specific loss of LMO4. In our LMO4-deficient mice,
LMO4 deletion was specific to forebrain glutamatergic neurons:
there is more than a 95% loss of LMO4 mRNA (Figure S1B) and
over 80% loss of LMO4 protein within the amygdala (Figure 4B;
the remaining 20% of LMO4 protein was likely due to expression
in non-glutamatergic neurons). The robust differences in anxiety
behavior we found in our mice, compared with that seen in the
hemizygous LMO4 deleted mice (Maiya et al., 2012), suggests
one of two possibilities: first, a near complete loss of LMO4
may be required to cause the changes in unconditioned anxiety
and amygdala function, and second, LMO4 in non-glutamatergic
neuronsmay exert opposite effects on anxiety behavior, and so a
non-specific deletion of this protein could result in a null pheno-
type due to contrasting effects within restricted cell types.
Further research is required to determine if these possibilities
explain the discrepancies between these studies.
Capitalizing on this newly determined relationship between
LMO4 and eCB signaling, we sought to determine the mecha-
nism by which these two systems interact. Consistent with
our previous findings within the hypothalamus (Pandey et al.,
2013), we found that the loss of LMO4 increased PTP1B activity
within the amygdala. Here, we showed for the first time that
increased PTP1B activity resulted in a constitutive decrease in
mGluR5 phosphorylation. This dephosphorylation impaired
mGluR5 function, as evidenced by a reduction in DHPG-stimu-
lated inward currents in BLA neurons, ERK phosphorylation,
and eCB-mediated LTDi, all of which were reversed by inhibition
of PTP1B. Importantly, this reversal was recapitulated by phar-
macological or genetic ablation of PTP1B exclusively within the
amygdala. The fact that PTP1B inhibition alleviated anxiety
in LMO4-deficient mice through a CB1 receptor-dependent
mechanism further supported the hypothesis that impaired
eCB signaling was the mediator of these changes. Collectively,
these data expand on the growing body of data indicating the
importance of eCB signaling for emotional homeostasis, as
well as identify an entirely novel intracellular cascade by which
eCB signaling is regulated within the amygdala.
It has been recently demonstrated that elevations in eCB
metabolism, and a consequential impairment in eCB signaling,
drives changes in amygdala plasticity and emotional behavior
following chronic stress (Gunduz-Cinar et al., 2013). Building
on these data, we found that chronic stress, through a glucocor-
ticoid-dependent pathway, caused a reduction in palmitoylated
LMO4 within the amygdala. Cell culture studies similarly showed
that prolonged exposure to corticosterone to neuronal cells simi-
larly caused a reduction in palmitoylation, and a subsequent
translocation of LMO4 from the cytosol to the nucleus, where
LMO4 functions as a transcription cofactor (Chen et al., 2002,
2007a, 2007b; Gomez-Smith et al., 2010; Schock et al., 2008)
but no longer interacts with PTP1B. In line with this finding,
PTP1B activity was elevated within the amygdala following
chronic stress, and inhibition of PTP1B during chronic stress
attenuated stress-induced suppression of eCB signaling within
the amygdala and normalized changes in anxiety from chronic
stress. As such, these data identify a novel intracellular mecha-
nism by which chronic stress can impair eCB signaling and pro-
mote anxiety.
Interestingly, trodusquemine had no effect on PTP1B activity
or anxiety in non-manipulated animals but was capable of
reversing the increased anxiety seen in the LMO4-deficient
mice and following exposure to chronic stress. The specificity
of this drug to selectively modulate increased anxiety suggests
a potential therapeutic advantage over current anxiolytics, such
as benzodiazepines, that possess addictive potential and are
general CNS depressants that exert robust effects on behavior
regardless of the state of stress or arousal (Schnabel, 1987).
More so, this selective effect on states of heightened anxiety par-
allels what is seen with drugs that boost eCB signaling (Hill et al.,
2013; Kathuria et al., 2003) whereby they exhibit few detectable
effects on resting behavior but modulate changes in anxiety in
response to arousal or stress. That the ability of trodusquemine
to suppress anxiety was sensitive to CB1 receptor blockade sug-
gests an alternatemeans to afford eCB-mediated relief of stress-
induced emotionality, that is, indirectly through inhibition of
PTP1B, as opposed to direct inhibition of eCB metabolism. This
is similar to a recent indirect approach using substrate-selective
inhibitors of COX-2, which also engages an eCB mechanism to
reduce anxiety (Hermanson et al., 2013). The fact that inhibition
of PTP1B in WT, non-stressed animals had no effect on eCB
content suggests that this is not a canonical mechanism of eCB
metabolism but a secondary pathway that can be engaged, by
chronic stress for example, to suppress eCB signaling.
Taken together, the current data highlight a novel LMO4-
PTP1B-eCB relationship within the amygdala that regulates anx-
iety and is engaged by chronic stress. These data reinforce the
importance of eCB signaling within the amygdala in the regula-
tion of emotional homeostasis, but also identify a novel putative
target for the regulation of stress-related mood and anxiety dis-
orders. Interestingly, inhibition of PTP1B has recently been
shown to reduce diet-induced obesity, and trodusquemine
has undergone phase I trials for obesity. Metabolic syndrome
and other obesity-related diseases are typically comorbid with
mood and anxiety disorders (Lin et al., 2008; Pouwer, 2009),
and co-treatment of these conditions has remained a therapeu-
tic challenge. In this regard, the exploration of whether PTP1B in-
hibition is capable of modulating changes in emotional behavior
related to obesity remains to be determined, but a recent report
has identified that eCB signaling within the amygdala limits
changes in anxiety in obese states (Blasio et al., 2013), high-
lighting the potential utility of PTP1B inhibition given its ability
to regulate eCB signaling. As such, the relationship between
LMO4, PTP1B and eCB signaling may prove to be relevant to
our understanding of the relationship between stress, meta-
bolism, and emotional behavior.EXPERIMENTAL PROCEDURES
Animals
CamK2aCre//LMO4flox/flox (LMO4KO) and LMO4flox/flox (WT) mice were bred
on a CD-1 background as described previously (Qin et al., 2012; Schocket al., 2008; Zhou et al., 2012). All animal use was approved by the University
of Ottawa Animal Care Committee in accordance with guidelines of the
Canadian Council on Animal Care.
Drugs and Anxiety Behavior Tests
See Supplemental Experimental Procedures for details.
Lipid Extraction from Tissue and Mass Spectrometric Detection
of eCBs
These procedures have been described previously (Dincheva et al., 2015) and
are addressed in detail in Supplemental Experimental Procedures.
Stereotactic Injection of Lentivirus
Lentiviral vectors (0.4 ml, 13 109 transduction units/ml at a rate of 0.05 ml/min)
expressing GFP reporter and PTP1B shRNA or control shRNAwere stereotac-
tically injected into the amygdala on both sides. See Supplemental Experi-
mental Procedures for viral vector preparation and stereotactic coordinates.
Twenty-one days later, amygdalae were isolated to examine the expression
of GFP by fluorescence imaging and PTP1B by immunoblot.
Stress Protocol
Male mice aged 6 to 7 weeks were subjected daily to 30 min of tube re-
straint in 50 ml conical tubes with ventilation holes for 8 consecutive days
(between 10 a.m. and noon). Control mice were left undisturbed in their
home cages except for necessary handling to maintain tail markings
throughout 8 days.
Corticosterone Radioimmunoassay
Mice were decapitated in the morning, and plasma corticosterone was
measured by radioimmunoassay following the manufacturer’s protocol using
the Corticosterone 125I RIA kits (MP Biomedicals).
Cell Culture, Plasmids, and Transfections
See Supplemental Experimental Procedures for details of the use of F11
neuronal cells, transfection protocol, and expression vectors of LMO4
cDNA, control scrambled shRNA, or LMO4-specific shRNA.
PTP1B Phosphatase Activity Assay
PTP1B phosphatase activity in extracts from amygdalar wedges or F11 cells
was measured with the PhosphoSeek PTP1B Assay Kit (BioVision), with
appropriate controls (Pandey et al., 2013). As a control, F11 cells were treated
with the tyrosine phosphatase inhibitor pervanadate at 100 mM for 30 min.
RNA Extraction and Quantitative RT-PCR
Total mouse amygdalar RNA was extracted and purified from 1-month-old
mutant and control mice and analyzed as previously described (Qin et al.,
2012).
In Situ Hybridization
Tissues were prepared for in situ hybridization with digoxigenin-labeled anti-
sense or sense riboprobes, as previously described (Duquette et al., 2010).
GST Pull-Down, Immunoprecipitation, and Immunoblot Analysis
F11 cells were cotransfected with Flag-LMO4 and WT or a substrate-trap-
ping mutant (D181A, D/A) GST-PTP1B (Stuible et al., 2008). Lysates were
pulled down with glutathione beads (Invitrogen). To detect oxi-PTP1B,
PTP1B was first immunoprecipitated with protein G-Sepharose-conjugated
rabbit anti-PTP1B antibody (Cell Signaling) and immunoblotted with a mouse
antibody specific to oxidized PTP active site (R&D Systems), as previously
described (Almontashiri et al., 2014; Pandey et al., 2013). Immunoprecipita-
tion of mGluR5 was carried out as detailed in Supplemental Experimental
Procedures. Antibodies were specific to phosphorylated (T202/Y204)-
ERK1/2, ERK1/2 (Cell Signaling), phosphorylated tyrosine (Invitrogen), and
LMO4 (Pandey et al., 2013). See Supplemental Experimental Procedures
for details. An average of 3 immunoblots were quantitated using ImageJ
(NIH).Neuron 85, 1319–1331, March 18, 2015 ª2015 Elsevier Inc. 1329
Palmitoylation Assay
Palmitoylation was assessed by a biotin exchange protocol, as we described
previously (Pandey et al., 2013).
Electrophysiology
Brain sections (300 mm) containing amygdala were prepared from 3- to 5-
week-old mice as described previously (Qin et al., 2012; Zaman et al., 2014)
and in detail in Supplemental Experimental Procedures.
Statistical Analysis
Data were acquired and analyzed using pClamp10.1, Sigma Stat 3.5, and
SPSS. Differences between treatments were analyzed using Student’s t test
for paired data or ANOVA followed by the Bonferroni post hoc test for multiple
comparisons. Significance was accepted at p < 0.05. See Tables S1 and S2 for
F values of main effects.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2015.02.015.
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